Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Eli Lilly

    Tag: Eli Lilly

    You Searched For "Eli Lilly"
    Lilly gets USFDA nod for Taltz(ixekizumab) for Pediatric Patients with Moderate to Severe Plaque Psoriasis

    Lilly gets USFDA nod for Taltz(ixekizumab) for Pediatric Patients with Moderate to Severe Plaque Psoriasis

    Medical Dialogues Bureau1 April 2020 12:30 PM IST
    Indianapolis: Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
    Eli Lilly delays its clinical trials during Coronavirus pandemic

    Eli Lilly delays its clinical trials during Coronavirus pandemic

    Medical Dialogues Bureau25 March 2020 3:00 PM IST
    Indianapolis: Eli Lilly and Company has provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company...
    Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata

    Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata

    Medical Dialogues Bureau19 March 2020 12:56 PM IST
    Baricitinib is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
    AbCellera, Eli Lilly join hands for Antibody Therapies for COVID-19

    AbCellera, Eli Lilly join hands for Antibody Therapies for COVID-19

    Medical Dialogues Bureau13 March 2020 9:00 AM IST
    Vancouver and Indianapolis: AbCellera and Eli Lilly and Company have recently announced that they have entered into an agreement to co-develop...
    USFDA accepts regulatory submission for tanezumab for management of chronic pain  due to osteoarthritis

    USFDA accepts regulatory submission for tanezumab for management of chronic pain due to osteoarthritis

    Medical Dialogues Bureau7 March 2020 10:00 AM IST
    Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF)...
    FDA Advisory approves Lillys CYRAMZA (ramucirumab) for type of lung Cancer

    FDA Advisory approves Lilly's CYRAMZA (ramucirumab) for type of lung Cancer

    Medical Dialogues Bureau1 March 2020 2:00 PM IST
    The ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License...
    USFDA approves Eli Lillys Trulicity (dulaglutide) for reduction in MACE in type 2 diabetes patient

    USFDA approves Eli Lilly's Trulicity (dulaglutide) for reduction in MACE in type 2 diabetes patient

    Medical Dialogues Bureau23 Feb 2020 12:00 PM IST
    New indication reflects a distinct patient population in the REWIND study, including primary people with multiple cardiovascular risk factors but...
    Top Cos in pharmaceutical supply chain develop Blockchain system to track prescription drugs, stop counterfeit

    Top Cos in pharmaceutical supply chain develop Blockchain system to track prescription drugs, stop counterfeit

    Medical Dialogues Bureau22 Feb 2020 4:04 PM IST
    Among the 24 participating companies are Amgen Inc, FedEx Corp, GlaxoSmithKline Plc, Novartis, AmerisourceBergen Corp , Sanofi ), Walgreens Boots...
    Eli Lilly Completes Acquisition of Dermira

    Eli Lilly Completes Acquisition of Dermira

    Medical Dialogues Bureau22 Feb 2020 9:45 AM IST
    INDIANAPOLIS : Eli Lilly and Company has announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition...
    Eli Lilly to provide Migraine drug Reyvow

    Eli Lilly to provide Migraine drug Reyvow

    Farhat Nasim4 Feb 2020 9:00 AM IST
    New Delhi: Eli Lilly and Company announced recently that REYVOW (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment...
    Eli Lilly new insulin to improve glycemic control in diabetics get positive opinion from EMA

    Eli Lilly new insulin to improve glycemic control in diabetics get positive opinion from EMA

    Farhat Nasim3 Feb 2020 3:03 PM IST
    The CHMP opinion is now referred for final action to the European Commission, which grants approval in the European Union. Lilly plans to market the...
    Drugmajors slash prices by 53pc for China bulk-buy program eligibility

    Drugmajors slash prices by 53pc for China bulk-buy program eligibility

    Medical Dialogues Bureau20 Jan 2020 10:00 AM IST
    Beijing: Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok